Dermatitis Eczema, Eczema, Nummular Dermatitis, Nummular Eczema
Conditions
Brief summary
This is an investigator-initiated, single-center, prospective, randomized, double-blind, interventional phase IIb study. Forty patients with clinically and histologically confirmed nummular eczema will be enrolled according to inclusion and exclusion criteria. Patients will be included after written informed consent is obtained. Prior to randomization, average application rate of class II topical steroids per day will be measured for 4 weeks. Subsequently, patients will be randomized in a 1:1 ratio into one arm to receive Apremilast 30 mg BID (following titration phase) for 16 weeks or a second arm receiving identically matching placebo for 16 weeks. From beginning of week 17, all patients will start an open-label treatment with Apremilast 30 mg BID until week 32. Concomitant use of topical steroids (class II) is allowed during the study. During the treatment period both placebo and Apremilast will be applied p.o. from week 0 until week 32.
Interventions
DRUGApremilast
This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
DRUGPlacebo Oral Tablet
This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
Sponsors
Celgene Corporation
Technical University of Munich
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Clinically confirmed diagnosis of nummular eczema 2. Biopsy-proven, meaning histology consistent with eczema (including PAS-staining) 3. PGA ≥ 3 on a 5 point scale 4. History of continuous use of topical steroids for the last 8 weeks 5. Age 18-85 years of age, body weight ≥ 40 kg and ≤ 160 kg 6. Signed informed consent from patient
Exclusion criteria
1. Permanent severe diseases, especially those affecting the immune system 2. Pregnancy or breast feeding 3. History or presence of epilepsy, significant neurological disorders, depression, suicidal ideation and behaviour, cerebrovascular attacks or ischemia 4. History or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy 5. Evidence of severe renal dysfunction defined as: * eGFR \< 30 ml/min/1,73 m2 (calculated using the MDRD formula) at screening (Visit 1) 6. Evidence of significant hepatic disease defined as: At screening (Visit 1): * Alkaline phosphatase \>3x upper limit of normal (ULN) or alkaline phosphatase \>2,5x ULN and total bilirubin \> 2xULN or * Aspartate transaminase (AST, SGOT\]) and alanine transaminase (ALT, SGPT\]) \> 2.5x upper limit of normal (ULN) 7. History of lymphoproliferative disorders 8. Patients who are considered potentially unreliable or where it is envisaged the patient may not consistently attend scheduled study visits 9. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant unless they use effective contraception during the study and for 4 weeks after study completion or discontinuation. The chosen form of birth control must be effective by the time the patient receives her first dose of study drug. 10. Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor tolerability or lack of access to veins) 11. Inability or unwillingness to undergo repeated punch biopsies 12. History of allergy to any component of the study medication 13. Current use of strong cytochrome P450 enzyme inducers (eg, rifampicin, phenobarbital, carbamazepine, phenytoin and St John's wort) 14. Patients with rare hereditary problems of galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption 15. Evidence of acute contact dermatitis at screening 16. Evidence of underweight, defined as BMI \< 18,5 kg/m2 17. Evidence of Zink deficiency defined as Zink level \< 20 µg/dL in serum
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PGA | week 16 | Number of Patients Achieving an Improvement (Decrease) in PGA (Physician Global Assessment) by two or more points at week 16 as compared to week 0 or achieving an absolute PGA of 0 or 1 at Week 16 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PGA score Arm 2 | week 32 | Change in PGA score compared to baseline and week 16 for patients in Arm 2 at week 32 \- Comparison of the first and the second 16 weeks of the trial in terms of the change in PGA score from baseline for patients in Arm 2 |
| Histology | week 16 | Significant histological improvement at week 16 - Assessed by reduction of epidermal thickness \> 30% or reduction of inflammatory infiltrate \> 50 % compared to histological findings on baseline. |
| Use of topical steroids | week 16 and 32 | Change From Baseline in the Reduction of the Use of Topical Steroids at week 16 and 32 \- Prior to randomization and during the treatment, average application rate of class II topical steroids per day will be calculated. Participants will receive prednicarbate from the study centre. On each visit the tube will be weighed to measure usage. |
| Pruritus Visual Analog Scale (VAS) | week 16 and 32 | Change From Baseline in Pruritus Visual Analog Scale (VAS) Score at Week 16 and 32 |
| TSQM | week 16 and 32 | Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) Score at Week 16 and 32 |
| Safety: Safety of Apremilast will be Assessed by Evaluating Adverse Events (AEs) - Type, frequency, severity, and relationship of the AEs to apremilast | week 36 | Safety of Apremilast will be Assessed by Evaluating Adverse Events (AEs) - Type, frequency, severity, and relationship of the AEs to apremilast |
| EASI | week 16 and 32 | EASI 50 score at week 16 and 32 (Eczema Area and Severity Index) |
| Transepidermal Waterloss (TEWL) | week 16 and 32 | Change From Baseline in Transepidermal Waterloss (TEWL) at week 16 and 32 |
| DLQI | week 16 and 32 | Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 and 32 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory endpoint: Change From Baseline in metabolic functions at Week 16 and 32 - abdominal girth | week 16 and 32 | Assessed via physical examination (abdominal girth (cm))) |
| Exploratory endpoint: Change From Baseline in metabolic functions at Week 16 and 32 - serum parameters | week 16 and 32 | Assessed via serum parameters (glucose, HbA1c, cholesterol, HDL, LDL, Lipoprotein (a)) |
| Exploratory endpoint: Change From Baseline in metabolic functions at Week 16 and 32 - characterization of molecular (gene expression profil) | week 16 and 32 | Changes in metabolic functions during treatment with Apremilast vs. Placebo in the skin (biopsies at week 0 and week 16) as determined by RNA sequencing (RNAseq). |
| Exploratory endpoint: Change From Baseline in metabolic functions at Week 16 and 32 - weight | week 16 and 32 | Assessed via physical examination (weight (kg)) |
| Exploratory endpoint: Change From Baseline in metabolic functions at Week 16 and 32 - BMI | week 16 and 32 | Assessed via physical examination (BMI (kg/m2)) |
Countries
Germany
Outcome results
None listed